DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $836,436 | -2.7% | 3,371 | -5.9% | 0.08% | -1.3% |
Q2 2023 | $859,680 | -4.8% | 3,582 | 0.0% | 0.08% | -12.4% |
Q1 2023 | $902,807 | -33.9% | 3,582 | -30.4% | 0.09% | -39.5% |
Q4 2022 | $1,366,046 | -1.4% | 5,147 | -4.1% | 0.15% | -9.8% |
Q3 2022 | $1,386,000 | +1.8% | 5,368 | 0.0% | 0.16% | +8.7% |
Q2 2022 | $1,361,000 | -13.6% | 5,368 | 0.0% | 0.15% | -2.0% |
Q1 2022 | $1,575,000 | -9.5% | 5,368 | +1.4% | 0.15% | -1.3% |
Q4 2021 | $1,741,000 | +27.5% | 5,293 | +5.0% | 0.16% | +10.7% |
Q3 2021 | $1,366,000 | +20.5% | 5,043 | +19.4% | 0.14% | +18.6% |
Q2 2021 | $1,134,000 | +47.5% | 4,224 | +23.7% | 0.12% | +3.5% |
Q1 2021 | $769,000 | +0.9% | 3,416 | -0.4% | 0.11% | -5.8% |
Q4 2020 | $762,000 | +25.5% | 3,430 | +21.7% | 0.12% | +10.0% |
Q3 2020 | $607,000 | +38.6% | 2,818 | +13.8% | 0.11% | +26.4% |
Q2 2020 | $438,000 | +27.7% | 2,477 | 0.0% | 0.09% | +6.1% |
Q1 2020 | $343,000 | -9.7% | 2,477 | 0.0% | 0.08% | +9.3% |
Q4 2019 | $380,000 | +6.1% | 2,477 | 0.0% | 0.08% | +1.4% |
Q3 2019 | $358,000 | +14.7% | 2,477 | +13.5% | 0.07% | +17.5% |
Q2 2019 | $312,000 | +8.3% | 2,183 | 0.0% | 0.06% | +6.8% |
Q1 2019 | $288,000 | – | 2,183 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |